May 19, 2021

Subject: Availability of GALZIN® (zinc acetate) 25 mg and 50 mg Capsules

Dear Healthcare Professional:

We are pleased to inform you that GALZIN® (zinc acetate) 25 mg and 50 mg Capsules are now back in inventory effective May 14, 2021. Teva will prioritize and expedite the processing of GALZIN orders to our direct customers in an effort to restock them as quickly as we can.

**Pharmacies** should contact their wholesaler(s) directly as Teva is actively fulfilling and shipping product to them.

**If you have any questions** about GALZIN, please contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872.

As indicated in our previous communications, healthcare providers should report adverse events associated with the use of GALZIN® capsules to Teva at 1-888-838-2872, Option 3 and then Option 4.

Adverse events, medication errors or quality problems experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting Program either online, by regular mail, or by fax:

- Complete and submit the report Online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)
- Regular mail or Fax: Download form [www.fda.gov/MedWatch/getforms.htm](http://www.fda.gov/MedWatch/getforms.htm) or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

Sincerely,

Denisa Hurtukova, MD  
Vice President, Head of North America Medical Affairs  
Teva Pharmaceuticals
INDICATION

GALZIN® (Zinc Acetate) therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent, an agent that binds to copper. Wilson’s disease results in a build-up of copper in the body.

IMPORTANT SAFETY INFORMATION

Do not use GALZIN if you are allergic to any of the ingredients in the product formulation.

GALZIN is not recommended for the initial treatment in patients with symptoms because of the delay in time it takes for zinc acetate to become effective in reducing copper levels. Patients who are having symptoms should be treated initially with copper binding agents (chelating agents).

GALZIN can cause stomach irritation. It may cause increases of liver and pancreatic enzymes that may last for weeks to months suggesting pancreatitis, an inflammation of the pancreas. The enzyme levels normally return to the high-normal range within the first one or two years of zinc therapy. There have been rare cases of death due to overdose of zinc acetate or with use of zinc acetate as initial treatment in patients with advanced liver disease.

Pregnancy Category: A. Studies in pregnant women have not shown that zinc acetate or zinc sulfate increases the risk of fetal abnormalities if taken during all trimesters of pregnancy. Zinc acetate should be used during pregnancy only if clearly needed. Zinc does appear in breast milk and zinc-induced copper deficiency in the nursing baby may occur. Therefore, it is not recommended to nurse while taking Galzin. No patients below the age of 10 years have been studied.

Patients should take GALZIN on an empty stomach, at least one hour before or two to three hours after meals. Capsules should be swallowed whole, not opened or chewed. In the rare event of gastrointestinal intolerance, generally occurring with the morning dose, this dose may be taken between breakfast and lunch.

Patients must be monitored by their doctors to determine if the zinc acetate therapy is adequate. People with Wilson’s disease should reduce their dietary copper intake. Patients must adhere strictly to their treatment regimen.

Please see accompanying full Prescribing Information.
**GALZIN® (Zinc Acetate) Capsules**

**DESCRIPTION**

Zinc acetate as the dihydrate is a salt of zinc used to inhibit the absorption of copper in patients with Wilson’s disease. Its structural formula is:

\[
\text{C}_2\text{H}_4\text{O}_2\text{Zn}(\text{H}_2\text{O})_2
\]

Zinc acetate occurs as white crystals or granules, freely soluble in water and in boiling alcohol, and slightly soluble in alcohol.

GALZIN® (Zinc Acetate) Capsules contain the equivalent of 25 or 50 mg of zinc, in addition to corn starch and magnesium stearate in gelatin capsules. The 25 mg capsule shells contain titanium dioxide and the 50 mg capsule shells contain titanium dioxide, methylparaben and propylparaben. The 25 mg capsule shells contain FD&C Blue #1; the 50 mg capsule shells contain FD&C Red #40, D&C Red #28, and D&C Yellow #10.

**CLINICAL PHARMACOLOGY**

**Introduction**

Wilson’s disease (hepatolenticular degeneration) is an autosomal recessive metabolic defect in hepatic excretion of copper in the bile, resulting in accumulation of excess copper in the liver, and subsequently in other organs, including the brain, kidneys, eyes, bone, and muscles. In this disease, hepatocytes store excess copper, but when their capacity is exceeded copper is released into the blood and is taken up in extrahepatic sites, such as the brain, resulting in motor disorders (ataxia, tremors, speech difficulties) and psychiatric manifestations (irritability, depression, deterioration of work performance). Redistribution of excess copper in hepatocytes leads to hepatocellular injury, inflammation, necrosis, and eventual cirrhosis. Patients may present clinically with predominantly hepatic, neurologic, or psychiatric symptoms. Zinc induces the production of metallothionein in the enterocyte, a protein that binds endogenously secreted copper such as that from the saliva, gastric juice and bile. The active moiety in zinc acetate is zinc cation. Regardless of the ligand, zinc does not provide useful information on zinc bioavailability at the site of action.

Zinc acetate is a 25% zinc–50% acetate solution, which is 100% ionized in the plasma. Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS; Monitoring Patients). The disease has been treated by restricting copper in the diet, and the use of zinc acetate has been found to detoxify copper. Once the patient's symptoms have stabilized clinically, maintenance treatment begins. Clinical measures are used to determine whether the patient remains stable (See PRECAUTIONS: Monitoring Patients).

The active moiety in zinc acetate is zinc cation. Regardless of the ligand, zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper such as that from the saliva, gastric juice and bile. Zinc induces the production of metallothionein in the enterocyte, a protein that binds copper thereby preventing its serumal transfer into the blood. The bound copper is then lost in the stool following desquamation of the intestinal cells.

**Pharmacokinetics**

Because the proposed site of action of zinc is an effect on copper uptake at the level of the intestinal cell, pharmacokinetic evaluations based on blood levels of zinc do not provide useful information on zinc bioavailability at the site of action. Determinations of zinc content in the liver and the plasma zinc concentration after the oral administration of zinc acetate have yielded inconsistent results. However, foods and beverages have been shown to decrease the uptake of zinc thereby decreasing the levels of zinc in the plasma of healthy volunteers. For this reason, the oral dose of zinc should be separated from food and beverages, other than water, by at least one hour.

**Pharmacodynamics**

In pharmacodynamic studies, the methods used included net copper balance and radiolabeled copper uptake in Wilson’s disease patients. These studies showed that a regimen of 50 mg t.i.d. of zinc acetate was effective in inducing a negative mean copper balance (-0.44 mg/day) and an adequate mean 64Cu uptake (0.82% of the administered dose). A regimen of 25 mg t.i.d. of zinc acetate was also found to be an adequate dose regimen, and not shown to be inferior to 50 mg t.i.d. Dose related toxicity was not found in this study.

**Symptomatic Patients Initially Treated With a Chelating Drug**

Clinical parameters such as neuropsychiatric status including evaluation of speech, and liver function tests were followed as the patients continued therapy on an adequate zinc acetate dose regimen. One hundred and thirty-three patients were followed for up to 14 years. There was no deterioration of neuropsychiatric function including speech and biochemical liver function tests, including bilirubin, transaminases, alkaline phosphatase and lactate dehydrogenase. The liver function tests remained either within normal range or slightly above the upper limit of normal for up to 9 years of treatment.

**Pre-symptomatic Patients**

In this study 30 pre-symptomatic patients were followed for up to 10 years. Diagnosis of the pre-symptomatic Wilson’s disease was made on the basis of a liver copper value greater than 200 µg of copper per gram dry weight of tissue. Clinical measures were used to determine whether the patient remains stable (See PRECAUTIONS: Monitoring Patients). The active moiety in zinc acetate is zinc cation. Regardless of the ligand, zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper such as that from the saliva, gastric juice and bile. Zinc induces the production of metallothionein in the enterocyte, a protein that binds copper thereby preventing its serumal transfer into the blood. The bound copper is then lost in the stool following desquamation of the intestinal cells.

In a study in the Netherlands, using zinc sulfate, 27 patients were followed up to 29 years by mainly clinical parameters such as tremors, dystarthis, dystonia, ataxia and Kayser-Fleischer rings. No deterioration of the clinical status was observed. In some cases, Kayser-Fleischer rings disappeared and clinical signs and symptoms improved.

**Pregnant Patients**

Included in a continuing single center United States trial are 19 symptomatic and presymptomatic women who became pregnant and continued Galzin therapy. These women delivered 26 live birth babies. At the time of delivery, the duration of zinc acetate therapy had ranged from 0.7 to 13.7 years. At the time of delivery all patients were using zinc acetate. The zinc acetate dosage at the start of pregnancy ranged from 25 to 50 mg two to three times a day. Two patients were being treated with penicillamine at the start of pregnancy and were switched to zinc acetate during the second month of pregnancy.

Urinary copper excretion was measured to monitor the copper status. Twenty-four hour urine excretion of copper indicated adequate control of copper levels in most patients before and during pregnancies. The results also indicated that during pregnancy, the mothers’ health was protected by zinc acetate therapy, and no adverse effects on liver or neurological functions were reported. Limited pregnancy outcome data indicates an incidence of miscarriages consistent with those in the general population. From this limited experience, the rate of birth defects is 7.7%, while the rate in the general population is 4%.

**INDICATIONS AND USAGE**

Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS; Monitoring Patients).

---

**Table: Dose Regimen vs Mean Copper Balance**

<table>
<thead>
<tr>
<th>Dose Regimen (mg zinc x number of daily doses)</th>
<th>N*</th>
<th>Mean Copper Balance (mg/day)</th>
<th>Number of Patients Inadequately Controlled/Total number of patients studied</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 x 3</td>
<td>70</td>
<td>-0.36</td>
<td>6/70</td>
</tr>
<tr>
<td>50 x 2</td>
<td>5</td>
<td>-0.16</td>
<td>0/5</td>
</tr>
<tr>
<td>25 x 4</td>
<td>5</td>
<td>-0.21</td>
<td>0/5</td>
</tr>
<tr>
<td>25 x 3</td>
<td>11</td>
<td>-0.18</td>
<td>1/11</td>
</tr>
<tr>
<td>37.5 x 2</td>
<td>4</td>
<td>-0.02</td>
<td>1/4</td>
</tr>
<tr>
<td>75 x 1</td>
<td>8</td>
<td>0.16</td>
<td>2/8</td>
</tr>
<tr>
<td>25 x 2</td>
<td>4</td>
<td>0.15</td>
<td>1/4</td>
</tr>
<tr>
<td>25 x 1</td>
<td>10</td>
<td>-0.37</td>
<td>2/10</td>
</tr>
<tr>
<td>25 x 6</td>
<td>12</td>
<td>0.05</td>
<td>4/12</td>
</tr>
<tr>
<td>50 x 1</td>
<td>1</td>
<td>0.1</td>
<td>0/1</td>
</tr>
<tr>
<td>50 x 5</td>
<td>1</td>
<td>-0.3</td>
<td>1/11</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0.52</td>
<td>–</td>
</tr>
</tbody>
</table>

*N = number of copper balance studies. Some patients had more than one balance study, at different doses or at the same dose at widely separated intervals.

While all zinc acetate regimens appeared better than no therapy, there was little experience with doses other than 50 mg t.i.d. Once daily dosing did not appear to give satisfactory control in many cases, and would be inadequate in patients with poor compliance. Based on the limited data available 25 mg t.i.d. was also thought by many to be an adequate dose regimen, and not shown to be inferior to 50 mg t.i.d. Dose related toxicity was not found in this study.

**REFERENCES**

CONTRAINDICATIONS
Zinc Acetate Capsules are contraindicated in patients with known hypersensitivity to any of the components of the formulation.

PRECAUTIONS
General
Zinc acetate is not recommended for the initial therapy of symptomatic patients because of the delay required for zinc-induced increase in enterocytic metallothionein and blockade of copper uptake. Symptomatic patients should be treated initially, using chelating agents. During initial therapy, neurological deterioration may occur as stores of copper are mobilized. Once initial therapy has been completed, and the patient is clinically stable, maintenance treatment with zinc acetate can be considered, but patients may be continued on initial therapy as clinically indicated.

Information for Patients
Patients should take GALZIN® on an empty stomach, at least one hour before or two to three hours after meals. Capsules should be swallowed whole, not opened or chewed. In the rare event of gastric intolerance with the morning dose, this dose may be taken between breakfast and lunch. Patients must be clinically monitored to determine the adequacy of zinc acetate therapy. Since strict adherence to the zinc regimen is essential for optimal control of copper distribution and metabolism, the physician must reinforce the need for compliance at each contact with the patient.

Monitoring Patients
Patients should be monitored primarily by assessment of existing signs and symptoms of Wilson’s disease and 24-hour urinary copper. Neuropsychiatric evaluations including speech as well as liver function tests including bilirubin and aminotransferases should be done as appropriate.

The urinary excretion of copper is an accurate reflection of the body status of copper when patients are not on chelation therapy. The clinician should be aware that urinary copper levels are usually increased with chelation therapy such as penicillamine or trientine. Adequate zinc therapy will eventually decrease urinary copper excretion to 125 μg per 24 hours or less. A significant trend upward indicates impending loss of copper control. The non-ceruloplasmin plasma copper (also known as free copper) is obtained by subtracting the ceruloplasmin-bound copper from the total plasma copper. Each mg of ceruloplasmin contains 3 μg of copper. In the United States, non-ceruloplasmin plasma copper concentration was kept below 20 μg/dL.

Monitoring of Patients
At each contact with the patient.

Drug Interactions
Pharmacodynamic studies in Wilson’s disease patients failed to demonstrate drug interactions between zinc acetate (50 mg t.i.d.) and ascorbic acid (1 g daily), penicillamine (1 g daily), and trientine (1 g daily). Therefore, precautions for zinc acetate are not necessary when Wilson’s disease patients are taking vitamin C or approved chelating agents. However, no data are available to demonstrate that zinc acetate should be added to other drugs used for the treatment of Wilson’s disease patients or is safe.

Nursing Mothers
Zinc does appear in breast milk and zinc-induced copper deficiency in the nursing baby may occur. Therefore, it is recommended that women on zinc therapy not nurse their babies.

Pediatric Use
Results of observations in a small number of patients in the two clinical trials suggest that pediatric patients aged 10 years and above can be adequately maintained at doses between 75 to 150 mg elemental zinc daily in divided doses. No patients below the age of 10 years have been studied.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Zinc acetate has not been tested for its carcinogenic potential in long-term animal studies, for its mutagenic potential or for its effect on fertility in animals. However, testing with other salts of zinc (zinc oxide, zinc stearate, zinc sulfate) did not reveal a mutagenicity potential in vitro Ames assays, and human embryonic lung cell chromosomal aberration assay, and in vivo rat dominant lethal assay, and rat bone marrow cell chromosomal aberration assay. Other salts of zinc (zinc oxide, zinc chloride, zinc citrate, zinc maleate, zinc carbonate, zinc sulfate) and pure zinc dust at oral doses up to 326 mg/Kg/day (18 times the recommended human dose based on body surface area) were found to have no effect on fertility and reproductive performance of male and female rats.

Pregnancy: Teratogenic Effects
Studies in pregnant women have not shown that zinc acetate or zinc sulfate increases the risk of fetal abnormalities if administered during all trimesters of pregnancy. If this drug is used during pregnancy, the possibility of fetal harm appears remote. Because studies cannot rule out the possibility of harm, zinc acetate should be used during pregnancy only if clearly needed. While zinc acetate should be used during pregnancy only if clearly needed, copper toxicosis can develop during pregnancy if anti-copper therapy is stopped.

Oral teratology studies have been performed with zinc sulfate in pregnant rats at doses up to 42.5 mg/Kg/day (2 times the recommended human dose based on body surface area), mice at doses up to 30 mg/Kg/day (1 time the recommended human dose based on body surface area), rabbits at doses up to 60 mg/Kg/day (6 times the recommended human dose based on body surface area) and hamsters at doses up to 88 mg/Kg/day (5 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to zinc sulfate. (See CLINICAL TRIALS).

ADVERSE REACTIONS
Clinical experience with zinc acetate has been limited. The following adverse reactions have been reported in patients with Wilson’s disease on zinc therapy: a death following overdosage with zinc sulfate (See OVERDOSAGE) and a death in a patient with advanced liver disease and hemolytic crisis where zinc sulfate was used as initial treatment; gastric irritation; elevations of serum alkaline phosphatase, amylase and lipase lasting from weeks to months suggesting pancreatitis. The levels usually return to high normal within the first one or two years of zinc therapy.

Drug Abuse and Dependence
Zinc acetate has no potential for abuse, and it is not related pharmacologically or structurally to any other drug known to have abuse potential.

OVERDOSAGE
Acute oral overdosage with inorganic salts of zinc in humans is reported rarely. In the event of overdosage, the unabsorbed zinc salt should be removed from the stomach by lavage as quickly as possible. The plasma level of zinc should be measured, and heavy metal chelation therapy should be considered if the plasma level of zinc is elevated markedly (>1000 μg/dL). In addition, any signs or symptoms of toxicity should be treated as medically indicated.

One fatality associated with overdosage of zinc sulfate has been reported. The death of this adult woman followed the accidental ingestion of approximately 28 g of zinc sulfate. Death occurred on the fifth day after ingestion and was attributed to renal failure. Hemorrhagic pancreatitis and hyperglycemic coma resulted from the overdose. The amount ingested was 500 mg/Kg of zinc sulfate, a value that is in the same order of magnitude as that found to be lethal in animals.

DOSE AND ADMINISTRATION
The recommended adult dose is 50 mg as zinc three times daily (See CLINICAL TRIALS).

Since 25 mg t.i.d. is also an effective dose in children 10 years of age or older or in women who are pregnant, it may be advisable to use a dose of zinc to 25 mg three times a day, as long as the patient is compliant with therapy. The dose can be raised to 50 mg t.i.d. if monitoring indicates a lessening of control (see PRECAUTIONS: Monitoring Patients).

Patients should take zinc acetate on an empty stomach, at least one hour before or two to three hours after meals. For additional information, see PRECAUTIONS.

HOW SUPPLIED
GALZIN® Zinc Acetate Capsules (25 mg zinc content) are #1 capsules with aqua blue opaque cap and body, imprinted “93-215.” Packaged in bottles of 250 (NDC 57844-215-52).

GALZIN® Zinc Acetate Capsules (50 mg zinc content) are #1 capsules with orange opaque cap and body, imprinted “93-208.” Packaged in bottles of 250 (NDC 57844-208-52).

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP Controlled Room Temperature. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

Rx only.

Rev. 7/2020

Distributed by:

Teva Pharmaceuticals USA, Inc.
Parsippany, NJ 07054

©2020 Teva Pharmaceuticals USA, Inc. All rights reserved.
GAL-40027